Trade

Jubilant Pharmova share price

Balanced risk
  • 44%Low risk
  • 44%Moderate risk
  • 44%Balanced risk
  • 44%High risk
  • 44%Extreme risk
  • 1,156.90(-1.16%)
    July 11, 2025 15:29:25 PM IST
    • NSE
    • BSE
  • Vol : 146.52K (NSE + BSE)
    Last 20 day avg : 406.58 K

Jubilant Pharmova is trading -1.16% lower at Rs 1,156.90 as compared to its last closing price. Jubilant Pharmova has been trading in the price range of 1,183.10 & 1,150.05. Jubilant Pharmova has given 6.03% in this year & -2.47% in the last 5 days. Jubilant Pharmova has TTM P/E ratio 16.91 as compared to the sector P/E of 22.90.There are 3 analysts who have initiated coverage on Jubilant Pharmova. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 153.60 Crores in its last quarter.Listed peers of Jubilant Pharmova include Eris Lifesciences (-0.54%), Alembic Pharmaceuticals (-0.21%), Jubilant Pharmova (-1.16%).The Mutual Fund holding in Jubilant Pharmova was at 3.66% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Jubilant Pharmova was at 17.23% in 31 Mar 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Key Metrics

Updated on Jul 12, 2025, 06:36 AM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.42
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    3.02
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    22.55
    Lower than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.96
    Medium volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.44
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
1,150.05
Highest
1,183.10
52 week range
Lowest
701.40
Highest
1,309.00
Jubilant Pharmova Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in March quarter by 9.68% from Rs 1928.80 crore to Rs 1758.60 crore, year-on-year
    • financial-insightsCompany has registered a profit of 153.60 cr vs a loss of 58.60 cr in the same quarter last year.
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Jubilant Pharmova Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 1,246.37
  • R2
  • 1,283.53
  • R3
  • 1,334.22
Pivot1,195.68
  • S1
  • 1,158.52
  • S2
  • 1,107.83
  • S3
  • 1,070.67
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Jubilant Pharmova Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Eris Lifesciences
Bullish
1,728.00-0.5423,733.6866.448.20.4362.42
Alembic Pharmaceuticals
Neutral
975.00-0.2119,165.8734.733.811.090.90
Jubilant Pharmova
Neutral
1,156.90-1.1618,427.2335.823.040.4238.19
Natco Pharma
Moderately Bullish
961.75-3.6517,225.899.252.290.620.06
Caplin Point Laboratories
Moderately Bearish
2,018.20-1.1715,394.4728.505.330.270.10
Jubilant Pharmova Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Jubilant Pharmova is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) holds a high stake in the company at 50.68%
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has increased by 0.27 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 0.02 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    Kotak Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 16.44
    • % of AUM 3.78
    Kotak Consumption Fund Regular Growth
    NA
    • Amount Invested (Cr.) 33.04
    • % of AUM 2.65
    Kotak Special Opportunities Fund Regular Growth
    NA
    • Amount Invested (Cr.) 52.83
    • % of AUM 2.53
    Kotak MNC Fund Regular Growth
    NA
    • Amount Invested (Cr.) 42.50
    • % of AUM 1.90
    HDFC Pharma and Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 30.32
    • % of AUM 1.78
    Jubilant Pharmova Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-05-16Audited Results & Final Dividend
    2025-01-31Quarterly Results
    2024-10-25Quarterly Results
    2024-07-19Quarterly Results
    2024-05-29Audited Results & Final Dividend
    About the company Jubilant Pharmova
    • IndustryBiotechnology & Drugs
    • ISININE700A01033
    • BSE Code530019
    • NSE CodeJUBLPHARMA
    Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services, and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
    • Management Info
    • Hari BhartiaNon-Executive Co-Chairman of the Board
    • Arvind ChokhanyGroup Chief Financial Officer, Whole-Time Director
    • Naresh KapoorCompliance Officer, Company Secretary
    • Arjun BhartiaJoint Managing Director, Executive Director
    • Priyavrat BhartiaManaging Director, Executive Director
    • Arul RamakrishanWhole-Time Director
    Jubilant Pharmova Share Price FAQs

    Jubilant Pharmova is trading at 1156.90 as on Fri Jul 11 2025 09:59:25. This is -1.16% lower as compared to its previous closing price of 1170.50.

    The market capitalization of Jubilant Pharmova is 18427.23 Cr as on Fri Jul 11 2025 09:59:25.

    The 52 wk high for Jubilant Pharmova is 1309.00 whereas the 52 wk low is 701.40

    Jubilant Pharmova can be analyzed on the following key metrics -

    • TTM P/E: 16.91
    • Sector P/E: 22.90
    • Dividend Yield: 0.43%
    • D/E ratio: 0.44

    Jubilant Pharmova reported a net profit of 839.40 Cr in 2025.

    The Mutual Fund Shareholding was 3.66% at the end of 31 Mar 2025.